Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia
BuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in t...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1444967/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561229043171328 |
|---|---|
| author | Ruiyin Tang Guanlin Xiao Yanchang Liu Dezheng Jia Zhihao Zeng Canchao Jia Dongmei Li Yangxue Li Jieyi Jiang Sumei Li Xiaoli Bi |
| author_facet | Ruiyin Tang Guanlin Xiao Yanchang Liu Dezheng Jia Zhihao Zeng Canchao Jia Dongmei Li Yangxue Li Jieyi Jiang Sumei Li Xiaoli Bi |
| author_sort | Ruiyin Tang |
| collection | DOAJ |
| description | BuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in this study, we aimed to investigate the active components and mechanisms of BSTZC in treating HLP by integrating serum pharmacology, pharmacokinetics, network analysis, and experimental validation. We first established UPLC fingerprints, calibrated 23 common peaks, and identified 13 common peaks, and the similarity was greater than 0.99 for 10 batches. A total of nine metabolites from BSTZC were identified in serum and considered as PK markers. The pharmacokinetic parameters of the PK markers were compared between the control group and the model group through the pharmacokinetics study to determine the dynamic changes of representative components in rats. Compared with the control group, the Cmax and AUC0→t of OXY, IVT, IVL, and KPF-3-G were significantly higher (P< 0.05); the AUC0→∞ of OXY, PN, and IVT was significantly higher (P< 0.05); and the t1/2 of IVT, SA, and KPF-3-G was significantly different (P< 0.05). In vivo experiments showed that BSTZC and its active components could effectively alleviate lipid metabolism disorders and liver injury, with obvious lipid-lowering effects. Further studies showed that BSTZC alleviated HLP by inhibiting the PI3K/Akt signaling pathway, which was consistent with the results of the network analysis study. Our results revealed the active components and mechanisms of BSTZC in the treatment of HLP, which could provide useful information to guide the clinical application of BSTZC. |
| format | Article |
| id | doaj-art-f4dca67147964c1db6d1c63803d8e678 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-f4dca67147964c1db6d1c63803d8e6782025-01-03T04:12:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14449671444967Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemiaRuiyin Tang0Guanlin Xiao1Yanchang Liu2Dezheng Jia3Zhihao Zeng4Canchao Jia5Dongmei Li6Yangxue Li7Jieyi Jiang8Sumei Li9Xiaoli Bi10School of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaGuangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong, ChinaSchool of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaSchool of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaSchool of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaSchool of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaSchool of the Fifth Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaGuangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong, ChinaGuangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong, ChinaGuangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong, ChinaGuangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou, Guangdong, ChinaBuShao Tiaozhi Capsule (BSTZC), a novel drug in China, has been used to treat hyperlipidemia (HLP) in clinical practice for many years. Despite our previous studies suggesting that BSTZC can treat HLP, there is a lack of a rapid and systematic method to explore its active components. Therefore, in this study, we aimed to investigate the active components and mechanisms of BSTZC in treating HLP by integrating serum pharmacology, pharmacokinetics, network analysis, and experimental validation. We first established UPLC fingerprints, calibrated 23 common peaks, and identified 13 common peaks, and the similarity was greater than 0.99 for 10 batches. A total of nine metabolites from BSTZC were identified in serum and considered as PK markers. The pharmacokinetic parameters of the PK markers were compared between the control group and the model group through the pharmacokinetics study to determine the dynamic changes of representative components in rats. Compared with the control group, the Cmax and AUC0→t of OXY, IVT, IVL, and KPF-3-G were significantly higher (P< 0.05); the AUC0→∞ of OXY, PN, and IVT was significantly higher (P< 0.05); and the t1/2 of IVT, SA, and KPF-3-G was significantly different (P< 0.05). In vivo experiments showed that BSTZC and its active components could effectively alleviate lipid metabolism disorders and liver injury, with obvious lipid-lowering effects. Further studies showed that BSTZC alleviated HLP by inhibiting the PI3K/Akt signaling pathway, which was consistent with the results of the network analysis study. Our results revealed the active components and mechanisms of BSTZC in the treatment of HLP, which could provide useful information to guide the clinical application of BSTZC.https://www.frontiersin.org/articles/10.3389/fphar.2024.1444967/fullBuShao Tiaozhi Capsuleserum pharmacochemistrypharmacokineticsnetwork analysishyperlipidemia |
| spellingShingle | Ruiyin Tang Guanlin Xiao Yanchang Liu Dezheng Jia Zhihao Zeng Canchao Jia Dongmei Li Yangxue Li Jieyi Jiang Sumei Li Xiaoli Bi Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia Frontiers in Pharmacology BuShao Tiaozhi Capsule serum pharmacochemistry pharmacokinetics network analysis hyperlipidemia |
| title | Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia |
| title_full | Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia |
| title_fullStr | Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia |
| title_full_unstemmed | Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia |
| title_short | Integrated serum pharmacochemistry, pharmacokinetics, and network analysis to explore active components of BuShao Tiaozhi Capsule on hyperlipidemia |
| title_sort | integrated serum pharmacochemistry pharmacokinetics and network analysis to explore active components of bushao tiaozhi capsule on hyperlipidemia |
| topic | BuShao Tiaozhi Capsule serum pharmacochemistry pharmacokinetics network analysis hyperlipidemia |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1444967/full |
| work_keys_str_mv | AT ruiyintang integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT guanlinxiao integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT yanchangliu integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT dezhengjia integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT zhihaozeng integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT canchaojia integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT dongmeili integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT yangxueli integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT jieyijiang integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT sumeili integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia AT xiaolibi integratedserumpharmacochemistrypharmacokineticsandnetworkanalysistoexploreactivecomponentsofbushaotiaozhicapsuleonhyperlipidemia |